Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MIRM, HLVX, NAMS, KRYS, BBIO, and represent 38.33% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: ETNB (+$22M), EWTX (+$20M), APLS (+$16M), MDGL (+$16M), DYN (+$16M), GPCR (+$13M), DCPH (+$11M), IRON (+$7.5M), MGNX (+$5.8M), AGIO (+$5.1M).
- Started 5 new stock positions in Mirati Therapeutics, DYN, ETNB, GPCR, MDGL.
- Reduced shares in these 10 stocks: CRNX (-$42M), SNDX (-$17M), ELVN (-$14M), REPL (-$6.6M), , STRO, ADCT, PASG, GRTS, Theseus Pharmaceuticals.
- Sold out of its positions in ELVN, PASG, REPL, STRO, SNDX, PRTA, ADCT.
- Frazier Life Sciences Management was a net buyer of stock by $62M.
- Frazier Life Sciences Management has $1.9B in assets under management (AUM), dropping by 23.63%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 49 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 10.3 | $192M | 6.5M | 29.52 |
|
|
| Hillevax (HLVX) | 8.4 | $157M | 9.8M | 16.05 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 7.2 | $136M | 12M | 11.17 |
|
|
| Krystal Biotech (KRYS) | 6.6 | $123M | 989k | 124.06 |
|
|
| Bridgebio Pharma (BBIO) | 5.9 | $110M | 2.7M | 40.37 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 5.8 | $109M | 2.4M | 45.97 |
|
|
| Phathom Pharmaceuticals (PHAT) | 4.9 | $92M | 10M | 9.13 |
|
|
| Vaxcyte (PCVX) | 3.9 | $73M | 1.2M | 62.80 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 3.2 | $60M | 3.0M | 19.88 |
|
|
| Alpine Immune Sciences (ALPN) | 3.2 | $60M | +4% | 3.1M | 19.06 |
|
| Apellis Pharmaceuticals (APLS) | 2.8 | $53M | +44% | 885k | 59.86 |
|
| Rocket Pharmaceuticals (RCKT) | 2.4 | $46M | +8% | 1.5M | 29.97 |
|
| Disc Medicine (IRON) | 2.4 | $45M | +19% | 785k | 57.76 |
|
| Kalvista Pharmaceuticals (KALV) | 2.4 | $44M | +11% | 3.6M | 12.25 |
|
| Tarsus Pharmaceuticals (TARS) | 1.9 | $36M | 1.8M | 20.25 |
|
|
| Edgewise Therapeutics (EWTX) | 1.6 | $29M | +214% | 2.7M | 10.94 |
|
| Revolution Medicines (RVMD) | 1.5 | $29M | 998k | 28.68 |
|
|
| An2 Therapeutics (ANTX) | 1.5 | $29M | 1.4M | 20.49 |
|
|
| Arcutis Biotherapeutics (ARQT) | 1.5 | $28M | 8.8M | 3.23 |
|
|
| Aerovate Therapeutics (AVTE) | 1.5 | $27M | 1.2M | 22.63 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.3 | $24M | 3.7M | 6.44 |
|
|
| Macrogenics (MGNX) | 1.2 | $23M | +33% | 2.4M | 9.62 |
|
| ACADIA Pharmaceuticals (ACAD) | 1.2 | $23M | +15% | 731k | 31.31 |
|
| 89bio (ETNB) | 1.2 | $22M | NEW | 2.0M | 11.17 |
|
| Merus N V (MRUS) | 1.1 | $21M | 747k | 27.50 |
|
|
| Oric Pharmaceuticals (ORIC) | 1.1 | $20M | 2.1M | 9.20 |
|
|
| Anaptysbio Inc Common (ANAB) | 1.0 | $19M | 900k | 21.42 |
|
|
| Savara (SVRA) | 1.0 | $19M | 4.0M | 4.70 |
|
|
| Soleno Therapeutics (SLNO) | 1.0 | $19M | 465k | 40.25 |
|
|
| Cerevel Therapeutics Hldng I (CERE) | 0.9 | $17M | 393k | 42.40 |
|
|
| Deciphera Pharmaceuticals (DCPH) | 0.9 | $17M | +176% | 1.0M | 16.13 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.9 | $16M | NEW | 69k | 231.38 |
|
| Dyne Therapeutics (DYN) | 0.8 | $16M | NEW | 1.2M | 13.30 |
|
| Silence Therapeutics Ads (SLN) | 0.8 | $15M | 881k | 17.37 |
|
|
| Tyra Biosciences (TYRA) | 0.8 | $14M | 1.0M | 13.85 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $14M | -74% | 398k | 35.58 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.7 | $13M | NEW | 317k | 40.76 |
|
| Arvinas Ord (ARVN) | 0.6 | $12M | 285k | 41.16 |
|
|
| Cogent Biosciences (COGT) | 0.6 | $12M | +32% | 2.0M | 5.88 |
|
| Agios Pharmaceuticals (AGIO) | 0.6 | $12M | +79% | 523k | 22.27 |
|
| Apogee Therapeutics (APGE) | 0.6 | $11M | 400k | 27.94 |
|
|
| Trevi Therapeutics (TRVI) | 0.5 | $9.9M | +7% | 7.4M | 1.34 |
|
| Theseus Pharmaceuticals | 0.5 | $8.6M | -5% | 2.1M | 4.05 |
|
| Intellia Therapeutics (NTLA) | 0.3 | $6.2M | 204k | 30.49 |
|
|
| Mirati Therapeutics | 0.3 | $4.7M | NEW | 80k | 58.75 |
|
| Bluebird Bio (BLUE) | 0.1 | $2.4M | 1.7M | 1.38 |
|
|
| Gritstone Oncology Ord (GRTS) | 0.1 | $2.1M | -27% | 1.0M | 2.04 |
|
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.1 | $1.6M | 500k | 3.13 |
|
|
| Aclaris Therapeutics (ACRS) | 0.0 | $278k | 264k | 1.05 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022
- Frazier Life Sciences Management 2022 Q2 filed Aug. 10, 2022
- Frazier Life Sciences Management 2022 Q1 filed May 16, 2022